Skip to search formSkip to main contentSkip to account menu

Ly-2127399

Known as: LY2127399, LY3022859 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tabalumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
SAT0005 Human C-Type Lectin Domain Family 4, Member C Gene Expression Level Helps Predict Future Clinical Response to Tabalumab Blockade of Baff in Rheumatoid Arthritis
Background Patients with rheumatoid arthritis (RA) exhibit substantial variability in both the magnitude and duration of their… 
2011
2011
Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma.
8012 Background: LY2127399 (LY) is a human mAb that neutralizes membrane-bound and soluble B cell activating factor (BAFF). LY… 
Review
2010
Review
2010
Treating multiple sclerosis with monoclonal antibodies: a 2010 update
Treating multiple sclerosis (MS) with monoclonal antibodies (mAbs) has been marked by both progress and setbacks in the past 2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)